Almonertinib as First-line Treatment in Patients With EGFR Mutations Positive in Advanced NSCLC With Brain Metastases
Clinical trial NCT04808752 · UNKNOWN
Trial details
- NCT number
- NCT04808752
- Sponsor
- Zhejiang Cancer Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-07-09
- Primary completion
- 2024-06-15
- Enrollment
- 63
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.